Skip to main content
SpringerLink
Log in

Midostaurin in FLT3 acute myeloid leukaemia worth extra cost

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Novartis Farmaceutica, SA, provided financial support for the study.

Reference

  • Arenaza A, et al. Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain. ClinicoEconomics and Outcomes Research : 13 Nov 2019. Available from: URL: https://doi.org/10.2147/CEOR.S222879

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Midostaurin in FLT3 acute myeloid leukaemia worth extra cost. PharmacoEcon Outcomes News 842, 18 (2019). https://doi.org/10.1007/s40274-019-6410-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6410-8

Search

Navigation